Chinese Natural Compound Decreases Pacemaking of Rabbit Cardiac Sinoatrial Cells by Targeting Second Messenger Regulation of F-channels
Authors
Affiliations
Tongmai Yangxin (TMYX) is a complex compound of the Traditional Chinese Medicine (TCM) used to treat several cardiac rhythm disorders; however, no information regarding its mechanism of action is available. In this study we provide a detailed characterization of the effects of TMYX on the electrical activity of pacemaker cells and unravel its mechanism of action. Single-cell electrophysiology revealed that TMYX elicits a reversible and dose-dependent (2/6 mg/ml) slowing of spontaneous action potentials rate (-20.8/-50.2%) by a selective reduction of the diastolic phase (-50.1/-76.0%). This action is mediated by a negative shift of the I activation curve (-6.7/-11.9 mV) and is caused by a reduction of the cyclic adenosine monophosphate (cAMP)-induced stimulation of pacemaker channels. We provide evidence that TMYX acts by directly antagonizing the cAMP-induced allosteric modulation of the pacemaker channels. Noticeably, this mechanism functionally resembles the pharmacological actions of muscarinic stimulation or β-blockers, but it does not require generalized changes in cytoplasmic cAMP levels thus ensuring a selective action on rate. In agreement with a competitive inhibition mechanism, TMYX exerts its maximal antagonistic action at submaximal cAMP concentrations and then progressively becomes less effective thus ensuring a full contribution of I to pacemaker rate during high metabolic demand and sympathetic stimulation.
Pacemaker Channels and the Chronotropic Response in Health and Disease.
Hennis K, Piantoni C, Biel M, Fenske S, Wahl-Schott C Circ Res. 2024; 134(10):1348-1378.
PMID: 38723033 PMC: 11081487. DOI: 10.1161/CIRCRESAHA.123.323250.